NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Frequently asked questions
What sector does NewAmsterdam Pharma Company N.V. (KH6) operate in?
NewAmsterdam Pharma Company N.V. belongs to the Other sector and operates in the Biotechnology industry.
What is NewAmsterdam Pharma Company N.V. (KH6) current stock price?
As of the latest data, NewAmsterdam Pharma Company N.V. stock price is €17.06, with a previous close of €16.71. NewAmsterdam Pharma Company N.V. gained €0.36 in the last trading session, representing a 2.13% increase.
What is NewAmsterdam Pharma Company N.V. (KH6) current market capitalization?
NewAmsterdam Pharma Company N.V. market cap is approximately 2.04 billion.
What is NewAmsterdam Pharma Company N.V. (KH6) Earnings Per Share (EPS)?
The trailing EPS is -€1.85.
What is NewAmsterdam Pharma Company N.V. (KH6) EBITDA?
NewAmsterdam Pharma Company N.V. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -56.74 million.
Does NewAmsterdam Pharma Company N.V. (KH6) pay dividends?
No. NewAmsterdam Pharma Company N.V. does not pay a dividend.
When is NewAmsterdam Pharma Company N.V. (KH6) next earnings report?
NewAmsterdam Pharma Company N.V. is expected to release its next earnings report on September 30, 2026.
What is NewAmsterdam Pharma Company N.V. (KH6) beta (volatility) score?
NewAmsterdam Pharma Company N.V. has a beta of 0.100, indicating lower volatility than the overall market.
